Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes

Atherosclerotic cardiovascular disease remains a major cause of death and disability, especially for high-risk familial hypercholesterolemia individuals. PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitors) reduce low-density lipoprotein cholesterol levels and cardiovascular event rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Myers, Kelly D., Farboodi, Niloofar, Mwamburi, Mkaya, Howard, William, Staszak, David, Gidding, Samuel, Baum, Seth J., Wilemon, Katherine, Rader, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665275/
https://www.ncbi.nlm.nih.gov/pubmed/31331194
http://dx.doi.org/10.1161/CIRCOUTCOMES.118.005404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665275/
https://www.ncbi.nlm.nih.gov/pubmed/31331194
http://dx.doi.org/10.1161/CIRCOUTCOMES.118.005404

Ejemplares similares